ketorolac has been researched along with Age-Related Macular Degeneration in 3 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Ketorolac or vehicle was instilled before the injection, and pain perception was recorded on a 0 to 100 Visual Analog Scale (VAS) immediately after the intravitreal administration." | 6.77 | Effect of ketorolac 0.5% drops on patients' pain perception during intravitreal injection procedure. ( Beredima, E; Georgakopoulos, CD; Makri, OE; Pharmakakis, NM; Vasilakis, PT, 2012) |
| "Ketorolac or vehicle was instilled before the injection, and pain perception was recorded on a 0 to 100 Visual Analog Scale (VAS) immediately after the intravitreal administration." | 2.77 | Effect of ketorolac 0.5% drops on patients' pain perception during intravitreal injection procedure. ( Beredima, E; Georgakopoulos, CD; Makri, OE; Pharmakakis, NM; Vasilakis, PT, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Russo, A | 1 |
| Costagliola, C | 1 |
| Delcassi, L | 1 |
| Romano, MR | 1 |
| Semeraro, F | 1 |
| Kim, SJ | 1 |
| Toma, HS | 1 |
| Georgakopoulos, CD | 1 |
| Vasilakis, PT | 1 |
| Makri, OE | 1 |
| Beredima, E | 1 |
| Pharmakakis, NM | 1 |
2 trials available for ketorolac and Age-Related Macular Degeneration
| Article | Year |
|---|---|
A randomised controlled trial of ranibizumab with and without ketorolac eyedrops for exudative age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodie | 2013 |
Effect of ketorolac 0.5% drops on patients' pain perception during intravitreal injection procedure.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; | 2012 |
1 other study available for ketorolac and Age-Related Macular Degeneration
| Article | Year |
|---|---|
Inhibition of choroidal neovascularization by intravitreal ketorolac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capillary Permeability; Choroidal Neovascularizati | 2010 |